89bio price target raised to $38 from $25 at UBS, says shares ‘undervalued’
UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...
89bio's SWOT analysis: pegozafermin's potential in MASH and SHTG markets
Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...
89bio (NASDAQ:ETNB) Price Target Raised to $38.00
(NASDAQ:ETNB – Get Free Report) had its price target boosted by stock analysts at UBS Group from $25.00 to $38.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a ...
Why 89bio Stock Lagged the Market Today
(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of ...
89bio's Pegozafermin Is Now Gaining Momentum
Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...
89bio, Inc. (NASDAQ:ETNB) Receives $30.33 Average Target Price from Analysts
Inc. (NASDAQ:ETNB – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that ...
Nasdaq4d
89bio, Inc. Prices Upsized Public Offering of Common Stock and Pre-funded Warrants Expected to Raise Approximately $250 Million
89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...
Investing3d
89bio's SWOT analysis: pegozafermin's potential in MASH and SHTG markets
89bio, Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of ...